25 September 2026 — QC Healthcare announced on 22 September that it would integrate Sanguina’s AI-based blood screening into its two 24/7 US telehealth platforms, the company said. The initial work covers My Pediatric Doctor and My Adult Doctor, with other QC Healthcare services under consideration.
Key points
- QC Healthcare plans to add Sanguina’s anaemia and circulation screening to its paediatric and adult virtual-care platforms.
- Sanguina analyses fingernail video; its Circulation Score measures blood return to the fingertips after pressure is released.
- The companies are considering later applications in oncology and veterans’ care, alongside deployments with healthcare organisations and employers.
My Pediatric Doctor and My Adult Doctor
QC Healthcare said the initial integration would put Sanguina’s anaemia and circulation screening into My Pediatric Doctor, its paediatric urgent and primary-care service, and My Adult Doctor, its equivalent adult service. Both platforms offer care around the clock nationwide, according to the company.
The proposed use is between-visit screening that clinicians could consider when deciding whether a patient needs laboratory testing, an in-person examination or a referral, QC Healthcare said. For paediatric care, the company identified development, nutrition and chronic conditions as settings where anaemia may be a concern.
In adult care, QC Healthcare identified fatigue, unexplained symptoms, chronic conditions and preventive evaluations as potential uses for blood-health information gathered between appointments. The company also cited pregnancy and postpartum care. These are proposed applications within its virtual-care services, rather than reported results from patients using the integrated tools.
Eric Doherty, QC Healthcare’s chief executive, said the partnership was intended to connect blood-health information gathered at home with licensed clinical care. Erika Tyburski, Sanguina’s chief executive and co-founder, said the tools were designed to give telehealth clinicians information that can be gathered between consultations.
Sanguina’s fingernail video and Circulation Score
Sanguina’s technology uses fingernail analysis to screen for anaemia, according to QC Healthcare. A second measure, the Circulation Score, is generated from video taken after a fingertip has been pressed and released. QC Healthcare said it records how quickly blood returns to the fingertip.
The company likened that circulation measure to a bedside assessment used by clinicians evaluating peripheral blood flow. It said trends gathered at home could give a telehealth clinician more context when considering follow-up for patients with symptoms or conditions associated with impaired circulation.
QC Healthcare said the score is intended to assist screening, monitoring and clinical decisions. It is not intended to diagnose a condition on its own or replace laboratory tests, physical examination or emergency assessment when those are needed, the company said.
The company also described frequent or on-demand anaemia screening as a potential use of Sanguina’s technology between appointments. That would differ from a laboratory blood draw in how information is collected, while leaving laboratory testing among the follow-up options available to a clinician.
My VA Doctor and My Oncology Doctor
QC Healthcare said it would evaluate later applications for My VA Doctor and My Oncology Doctor, two platforms it described as being in development. It identified monitoring and care coordination between oncology visits as a potential use for the latter service.
The companies also plan to pursue potential deployments with hospitals, health systems, employers, payers, maternal-health programmes, veterans’ organisations, oncology programmes and research partners, QC Healthcare said. Among the applications it identified were remote monitoring, prenatal and postpartum follow-up, chronic-disease management and follow-up after discharge.
The collaboration is also intended to support clinical validation, real-world evidence gathering and clinical trial work, Digital Health News reported. According to the companies, expansion into additional clinical applications would be subject to appropriate validation and regulatory review.
